Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: Preliminary investigation

Pharmacology

Volumn 95, Issue , 2015, Pages 22-28

  Perrone, Maria Grazia ^a   Lofrumento, Dario Domenico ^b   Vitale, Paola ^a   De Nuccio, Francesco ^b   La Pesa, Velia ^b   Panella, Andrea ^a   Calvello, Rosa ^a   Cianciulli, Antonia ^a   Panaro, Maria Antonietta ^a   Scilimati, Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

Author keywords

3 (5 Chlorofuran 2 yl) 5 methyl 4 phenylisoxazole (P6); COX 1 inhibition; Gastric damage

Indexed keywords

3 (5 CHLOROFURAN 2 YL) 5 METHYL 4 PHENYLISOXAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; 1,3-BUTYL ETHYLENE GLYCOL DISALICYLATE; ETHYLENE GLYCOL DERIVATIVE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; SALICYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; HYPEREMIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH GLAND; STOMACH INJURY; STOMACH MUCOSA; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GASTRIC MUCOSA; METABOLISM; PATHOLOGY;

ANIMALS; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ETHYLENE GLYCOLS; GASTRIC MUCOSA; MALE; MEMBRANE PROTEINS; MICE; SALICYLATES;

EID: 84921326394     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000369826     Document Type: Article

References (25)

1. Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K: Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal anti-inflammatory drugs. J Physiol 2001; 95: 21-27.
2. Tanaka A, Hase S, Miyazawa T, Takeuchi K: Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300: 754-761.
3. Perrone MG, Scilimati A, Simone L, Vitale P: Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 2010; 17: 3769-3805.
4. Fukai R, Zheng X, Motoshima K, Kakuta H: Significance and creation of novel cyclooxygenase-1 (COX-1) selective inhibitors. Yakugaku Zasshi 2011; 31: 347-351.
5. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM: Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001; 132: 1565-1573.
6. Di Nunno L, Vitale P, Scilimati A, Tacconelli S, Patrignani P: Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem 2004; 47: 4881-4890.
7. Vitale P, Tacconelli S, Perrone MG, Malerba P, Simone L, Scilimati A, Lavecchia A, Dovizio M, Marcantoni E, Bruno A, Patrignani P: Synthesis, pharmacological characterization and docking analysis of a novel family of diarylisoxazoles as highly selective COX-1 inhibitors. J Med Chem 2013; 56: 4277-4299.
8. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, Tacconelli S, Sacchetti A, D'Angelo S, Scilimati A, Sciulli MG, Patrignani P: De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
9. Calvello R, Panaro MA, Carbone ML, Cianciulli A, Perrone MG, Vitale P, Malerba P, Scilimati A: Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells. Pharmacol Res 2012; 65: 137-148.
10. Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A: PET radiotracer [ 18 F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem 2014; 80: 562-568.
11. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976; 72: 248-254.
12. Iwamoto J, Saito Y, Honda A, Matsuzaki Y: Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 2013; 19: 1673-1682.
13. Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlsson P, Bjarnason IT: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003; 52: 1537-1542.
14. Lazzarato L, Cena C, Rolando B, Marini E, Lolli ML, Guglielmo S, Guaita E, Morini G, Coruzzi G, Fruttero R, Gasco A: Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans. Bioorg Med Chem 2011; 19: 5852-5860.
15. Cirino G: Nitric oxide releasing drugs: from bench to bedside. Dig Liver Dis 2003; 35:S2-S8.
16. Fiorucci S, Distrutti E: COXIBs, CINODs and H 2 S-releasing NSAIDs: current perspectives in the development of safer non steroidal antiinflammatory drugs. Curr Med Chem 2011; 18: 3494-3505.
17. Sigthorsson G, Simpson RJ, WalleyM, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-1923.
18. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-492.
19. Wallace JL, McKnight W, Reuter BK, Vergnolle N: NSAID induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-714.
20. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 762-770.
21. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A: Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001; 7: 1923-1931.
22. Rainsford KD, Tsang S, Hunt RH, Al-Jehani N: Effects of non-steroidal anti-inflammatory drugs on prostaglandin H synthase isoenzyme 2 (cyclooxygenase 2) production by porcine gastric mucosa in organ culture. Inflammopharmacology 1995; 3: 299-310.
23. Peter J, Nartey L, Reichenbach S, Sterchi R, Dieppe PA: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
24. Barrio JR, Satyamuethy N, Huang SC, Petri A, Small GW, Kepe V: Dissecting molecular mechanisms in the living brain of dementia patients. Acc Chem Res 2009; 42: 842-850.
25. Choi SH, Aid S, Bosetti F: The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009; 30: 174-181.